TNP- 470 as a potential adjuvant Therapy for Cholangiocarcinoma

TNP- 470 as a potential adjuvant Therapy for Cholangiocarcinoma
TNP- 470,Therapy, TNP- 470 ,Cholangiocarcinoma
Issue Date
Dr LEE Jong-Wook Seoul project
TNP-470 exerts the effect on the growth in cancer cells and suppression on
tumor progression including in vitro and in animal model. However there is dose limiting
toxicity due to high dose of TNP-470 encountered with neurotoxic side effect in cancer patients.
Therefore, to overcome the side effect, it has been suggested by using as an adjuvant with
chemotherapeutic drugs and other adjuvant therapy.
Therefore, according to the urgent need in termination of cancers by applying TNP-470,
MetAP2 inhibitors in combination with chemotherapeutic drugs would be the effective strategy
for the treatment of several cancers including CCA.
Cholangiocarcinoma(CCA) is identified as an invasive and fetal cancer overall
worldwide deriving from biliary epithelium cells including intra-hepatic and extra-hepatic biliary
tract(Thongprasert et al., 2005) . In addition, CCA is a high infiltrating growth tumor with high
metastasis to lymph and blood vessel (Sriamporn et al., 2004). The malignancy of CCA is not
commonly clear to diagnose unless it becomes disseminate resulting in the poorly prognosis even
there are many experimental evidences indicating biomarkers and related molecules which
inhibited by anti-cancer drugs both in vitro and in vivo, but there is no any standard method to
treat CCA patient successfully.
To date, the efforts of researchers with various methods to prevent the initial incidence of
major risk factor such as Opisthorchis viverrini infection (Andoh et al., 2004; Kim et al., 2009;
Poomphakwaen et al., 2009). Altogether, many methods targeting to CCA treatment including
surgery, radiation, chemotherapy and other palliative treatments are tested to diminish CCA from
the worldwide (Czito et al., 2006; Aljiffry et al., 2009; Han et al., 2009), but there is not any an
effective method is conformed in clinical trial. Therefore, with the increasing of CCA prevalence
and the urgent need of the most effective methods to treat the patients in the worldwide.
Appears in Collections:
3.University of Health Sciences > Faculty of basic sciences > Others
Files in This Item:
Proposal presentation.pptxDownload


Items in LAOSpace are protected by copyright, with all rights reserved, unless otherwise indicated.